Chemed (NYSE:CHE – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.
Chemed Price Performance
Shares of NYSE:CHE opened at $594.36 on Friday. Chemed has a 1 year low of $512.12 and a 1 year high of $654.62. The stock’s fifty day moving average price is $550.98 and its 200-day moving average price is $563.76. The company has a market cap of $8.95 billion, a P/E ratio of 30.03, a PEG ratio of 2.15 and a beta of 0.48.
Insider Transactions at Chemed
In related news, VP Brian C. Judkins bought 145 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average cost of $519.50 per share, for a total transaction of $75,327.50. Following the completion of the transaction, the vice president now owns 1,678 shares of the company’s stock, valued at approximately $871,721. This trade represents a 9.46 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.32% of the company’s stock.
Institutional Investors Weigh In On Chemed
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
- Five stocks we like better than Chemed
- What Are Earnings Reports?
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- What is Put Option Volume?
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.